Abstract
Rapamycin (sirolimus) is an immunosuppressive drug approved by the Food and Drug Administration (FDA). It is also a leading candidate for targeting aging. Rapamycin and its analogs (everolimus, temsirolimus, ridaforolimus) inhibit the mammalian target of rapamycin (mTOR) kinase by binding to FK506-binding proteins (FKBP) and have a similar chemical structure that only differs in the functional group present at carbon-40. Analogs of rapamycin were developed to improve its pharmacological properties, such as low oral bioavailability and a long half-life. The analogs of rapamycin are referred to as "rapalogs."Rapamycin is the parent compound and should therewith not be called a "rapalog."
Original language | English |
---|---|
Pages (from-to) | 657-659 |
Number of pages | 3 |
Journal | Gerontology |
Volume | 69 |
Issue number | 6 |
Early online date | 6 Jun 2023 |
DOIs | |
Publication status | Published - Jun 2023 |
Bibliographical note
Funding Information:This article was funded by an unrestricted grant by the National University of Singapore and the Lien Foundation without any involvement in any parts of the work.
Publisher Copyright:
© 2023 Authors. All rights reserved.
Keywords
- Aging
- Mammalian target of rapamycin inhibitors
- Sirolimus